Ensysce Registers Resale of 433.9M Shares — Roughly 22x Its Current Share Count

summarizeSummary

Ensysce filed the resale S-3 for up to 433.9M shares underlying its Series C preferred — roughly 22x its 19.5M shares outstanding. The company gets no proceeds, and conversion still needs stockholder approval plus Nasdaq's $4.00 minimum bid price clearance.

check_boxKey Events · Financing and Capital Events · ENSC

• Resale S-3 Covers 433.9M Shares

  Registers up to 433,907,000 shares of common stock issuable on conversion of Series C preferred: 282,122,000 from the Cy merger, 120,260,000 from the PIPE, 22,166,000 tied to a clinical milestone, 7,183,000 from the 3i OATA and 2,176,000 from the Galephar manufacturing agreement.

• Overhang Is Roughly 22x Outstanding

  Against 19,456,794 shares outstanding as of October 19, 2026, the registered shares equal approximately 2230% of the current count; fully converted, the filing shows 453,363,794 shares outstanding.

• No Proceeds to the Company

  Ensysce sells nothing under this prospectus and receives no proceeds; the selling holders keep all sale proceeds and bear their own commissions, while Ensysce pays registration costs estimated at $119,347.

• Conversion Blocked Pending Two Approvals

  Preferred cannot convert until stockholder approval and completion of Nasdaq's initial listing process, which requires a $4.00 minimum bid price versus the $0.5029 last reported sale price on October 19, 2026; if approvals fail, the preferred stays non-voting and these shares cannot be issued.

auto_awesomeAnalysis · ENSC · Life Sciences

This is the resale registration Ensysce owed PIPE and Cy investors after the August 5 merger and financing, and it puts hard numbers on an overhang that was previously only described in prose. Up to 433,907,000 shares of common stock underlie the Series C preferred — against just 19,456,794 shares outstanding as of October 19, 2026, the filing itself pegs the registered shares at approximately 2230% of the current count. The company receives no proceeds; every dollar from any sale goes to the selling holders, so this is pure supply, not new capital. Two gates still stand between the preferred and actual selling: stockholders must approve conversion, and Nasdaq must complete the initial listing process, which includes a $4.00 minimum bid price requirement against a stock trading near $0.48. Until those clear, the shares cannot be issued or resold — but the registration removes the paperwork barrier, and a 180-day lock-up on Cy holders and Ensysce insiders expires 180 days after the August 5 closing. The filing also carries going-concern language from both Baker Tilly (Ensysce) and EisnerAmper (Cy), so the dilution lands on a balance sheet that already needed rescuing.